Epidemiology of Measles

Spread the Message

Read Time:5 Minute, 42 Second

1. Introduction

Measles (rubeola) is a highly contagious viral disease predominantly affecting children. Despite being vaccine-preventable, it continues to cause significant morbidity and mortality globally, particularly in low-resource settings. The epidemiological study of measles helps in understanding its patterns of transmission, distribution, and determinants—crucial for designing effective prevention and control strategies. By the end of this session, you’ll be able to:

Describe global, national, and local incidence trends.
Analyze risk factors and transmission dynamics.
Understand surveillance, outbreaks, and response mechanisms.
Review preventive strategies including vaccination programs.

2. Etiology, Transmission & Pathogenesis

Agent: Measles virus—an enveloped, negative-sense RNA paramyxovirus
Transmission: Airborne via respiratory droplets; virus remains viable in air/surfaces for up to 2 hours. With R₀ ≈ 12–18, 9 out of 10 susceptible individuals exposed to a case will become infected (cdc.gov).
Incubation: 10–12 days (up to 21 days)
Infectious period: ~4 days before to 4 days after rash onset
Pathogenesis: Entry via respiratory epithelium → rapid replication → viremia → widespread infection including respiratory tract, conjunctiva, and skin. Classic symptoms include high fever, cough, coryza, conjunctivitis, Koplik spots, and maculopapular rash.

Complications—otitis media, pneumonia, diarrhea, encephalitis, death.

3. Global Epidemiology

Pre-vaccination era: ~135 million cases/year, 8 million child deaths annually (pmc.ncbi.nlm.nih.gov).
COVID-19 impact: Disruption in routine immunization led to resurgence—10.3 million cases, 107,500 deaths in 2023, a 20% increase from 2022 (reuters.com).
WHO (Nov 2024): Global MCV1 coverage ~83%, the lowest since 2008; more than half the world at high risk for outbreaks in 2025 (people.com).
Europe (Apr 2025): ~22,500 cases across 29 countries, with 44% <5 years old; 14 deaths (thesun.co.uk).

Despite decline in high-income countries, global resurgence persists due to inequities and vaccine hesitancy.

4. India-Specific Epidemiology

4.1 Disease Burden & Trends

Before vaccination: 8 million deaths globally; India had high endemic transmission.
Post-introduction (1985 UIP): Case reduction from 252,000 (1987) to 36,900 (2007) (pmc.ncbi.nlm.nih.gov).
Genotypes: D4, D7, D8; recent years show B3, D4, D8 (pmc.ncbi.nlm.nih.gov).
VPD Surveillance (2011–2020): ≈559,000 cases and 4,209 deaths in <5 years; incidence dropped 10-fold by 2020 (628.8 to 52/million) (link.springer.com). CFR peaked at 3.68% in 2020.

4.2 Immunization Coverage & Campaigns

MCV1 introduced in 1985; MCV2 in 2010 (16–24 months); MRCV replaced in 2017 (link.springer.com, pmc.ncbi.nlm.nih.gov).
NFHS (2021): MCV coverage rose from 81.1%→87.9%; ~95% received at least one dose (pmc.ncbi.nlm.nih.gov).
Supplementary immunization activities like Mission Indradhanush and MR catch-up campaigns vaccinated >324 million children (2017–2020) (who.int).
Progress (2005–2021): MCV1+31%, MCV2 +204%; measles incidence declined 62%, rubella 49% (cdc.gov).
COVID-19 hit: MCRV-1 coverage dipped 95%→89%, MCV2 from 84%→82%; surveillance sensitivity dropped (cdc.gov).
2022: 42% of districts achieved target surveillance; India aims for measles-rubella elimination by 2023 (cdc.gov).

5. Risk Factors & Determinants

Individual: Infants <9 months (no maternal antibody?), unvaccinated <5s, immunocompromised, pregnant women.
Social: Poverty, overcrowding, poor sanitation, limited access to healthcare in remote areas (notably North‑East states: Sikkim, Mizoram, Arunachal with high incidence) (link.springer.com).
Systemic: Low vaccination coverage (<95%), immunity gaps, inadequate surveillance, disruptions (e.g. pandemics).
Behavioral/Contextual: Vaccine hesitancy driven by misinformation, fallout from COVID-19 (verywellhealth.com, time.com).

6. Surveillance and Outbreak Response

6.1 Surveillance Systems

Fever‑rash surveillance integrated under IDSP and WHO MR surveillance (who.int).
Case-based surveillance being scaled in 32 states, progressing toward national roll‑out (indianpediatrics.net).
Virological surveillance through 27 MR labs (WHO-accredited), including ICMR-VRDLs and NIV Mumbai for genotyping (who.int).
2022: ~77,665 serology, 32.7K molecular tests; results within 24 hours (who.int).

6.2 Outbreak Investigation & Response

RRT deployment for field investigations.
Lab-confirmed diagnosis—serology (IgM) + RT-PCR.
Drop in outbreak intervals due to rapid detection.
Integration with public health education and targeted immunization drives.

India achieved global standard discard rate (>2/100K) in late 2021 (en.wikipedia.org, who.int).

7. Vaccination Strategies & Prevention

7.1 WHO Recommended Schedule

Two-dose regimen: 9–12 months & 15–18 months (or 4–6 years depending on context) (en.wikipedia.org).
MMR coverage: single dose ≈93%, two dose ≈97% effectiveness (maine.gov).

7.2 India’s Immunization Landscape

Routine immunization under UIP with MR vaccine at 9 & 16 months; campaign doses via MI and MR SIAs .
India’s mission-based campaigns included catch-up drives targeting children up to 15 years.
MCV2 and MR uptake increased post-2010 and 2017 campaigns.

7.3 Herd Immunity

Protective threshold: ≥95% two-dose coverage for herd immunity.
Coverage gaps and vaccine hesitancy remain core issues (bmcpublichealth.biomedcentral.com, indianpediatrics.net, time.com).

8. Challenges and Future Directions

8.1 Challenges

Incomplete coverage: India remains second-highest globally for unvaccinated children (indianpediatrics.net).
Geographic disparities: North‑East states lag in coverage .
Surveillance limitations: Many districts remain silent or underreport cases (indianpediatrics.net).
Pandemic setbacks: disruption in routine immunization and surveillance capacity (cdc.gov).
Misinformation: vaccine hesitancy due to myths like autism link and COVID spill‑over doubt (time.com).

8.2 Future Strategies

Ramp up routine and catch-up immunization post-pandemic.
Expand case-based, lab-supported surveillance nationwide.
Strengthen equitable access especially to marginalized regions.
Combat vaccine misinformation via targeted behavioural interventions.
Boost measles-rubella achievements within the global push for elimination.

9. Role of Clinicians & Public Health Integration (≈100 words)

Watch for febrile rash illness; report promptly—both clinicians and pediatricians are critical sentinels.
Confirm diagnosis with laboratory support and document by case definition.
Educate family on vaccination schedules, importance of both doses.
Participate in outbreak response and immunization drives when needed.
Advocate for vaccines, dispel myths, address barriers to care.

10. Conclusion

Measles remains one of the most infectious yet preventable childhood diseases. Epidemiological analysis—tracking trends, assessing coverage, detecting outbreaks—shapes targeted public health responses. In India, strong progress has been achieved through UIP, supplementary immunization, and improved surveillance; but disparities, hesitancy, and lingering immunity gaps threaten elimination goals. As MBBS graduates and future healthcare providers, integrating clinical acumen with public health vigilance will be vital. Prompt identification, reporting, and advocacy will ensure we close the gap between measles control and elimination.

📚 Suggested Readings

Park’s Preventive & Social Medicine – Epidemiology and control
WHO India: Measles and Rubella elimination guidelines (indianpediatrics.net, time.com, drishtiias.com, bmcpublichealth.biomedcentral.com, who.int)
CDC measles surveillance reports
BMC Public Health (2011–2020 trends) (northandoverma.news, bmcpublichealth.biomedcentral.com)
Reuters, Time, People coverage on global trends